In vivo anticancer activities of vanillin thiosemicarbazone complexes with Co[II] and Ni[II]

The anticancer activities of vanillin thiosemicarbazone complexes with Co[II] and Ni[II] have been studied against Ehrlich ascites carcinoma [EAC] cells in Swiss albino mice. Both the complexes were administrated into the intraperitoneal cavity of the EAC-inoculated mice at two doses [5 and 7.5 mg/kg i.p.]. The anticancer activities were studied by monitoring the parameters such as cell growth inhibition, tumor weight measurement, survival time of EAC-bearing mice, as well as the changes in depleted hematological parameters due to tumorigenesis. All data were compared with those of a known standard drug bleomycin at the dose of 0.3 mg/kg [i.p.]. It has been found that these complexes significantly increased the life span of tumor-bearing mice and decreased the rate of growth and weight of tumor cells. They also restored modestly the depleted hematological parameters such as hemoglobin content, RBC count, and WBC count to normal. They enhanced the number of macrophages in normal mice with minor host toxicity. It is concluded that these compounds can be primarily considered as potent anticancer agents

Mercury[II] cystine complex as antineoplastic agent

Antineoplastic activity of mercury[II] cystine complex was studied against ehrlich ascites carcinoma [EAC] cells in Swiss Albino mice. Cell growth inhibition, increase of life span, haematological parameters, alkaline phosphatase activity of tumour bearing mice inoculated with EAC cells were studied with the test compound. It was found that this compound significantly inhibited the tumour cell growth, enhanced life span of the tumour bearing mice at dose 6 mg/kg i.p. Such treatment also restored the altered haematological parameters and serum alkaline phosphatase activity very closely towards normal. The compound can be considered as a potent antineoplastic agent

Antineoplastic activity of nickel [II] cystine complex against ehrlich ascites carcinoma in swiss albino mice

Ni[II]-cystine complex was synthesized by treating saturated aqueous solutions of Ni [II] acetate and L[-] cystine [in 1: 1 molar ratio]. The complex was used to study its antineoplastic activity against EAC cells in Swiss Albino mice. It was found that the Ni [II] complex restored the depleted haematological and biochemical parameters of the EAC bearing mice towards normal values and enhanced the longevity of such mice significantly. The test compound on the other hand showed negligible host toxicity. The results obtained were compared with those obtained with a standard anticancer drug bleomycin